Ella Mendelson

Ella Mendelson

Auto-generated profile, based on publicly available information

Ella Mendelson

Division of Epidemiology, Ministry of Health, 39 Yirmiyahu Street, Jerusalem 9101002, Israel; Central Virology Laboratory, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Israel

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1992 in Virology
Verified
Journal Article
Closed access
EWErnest Winocour
Ernest Winocour
LPLeopold Puzis
Leopold Puzis
SESara Etkin
Sara Etkin
TKTamar Koch
Tamar Koch
BDBernard Danovitch
Bernard Danovitch
SLSara Lavi
Sara Lavi

1 October 2017 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
RBRavit Bassal
Ravit Bassal
MWMerav Weil
Merav Weil
DCDani Cohen
Dani Cohen
DSDanit Sofer
Danit Sofer
EMElla Mendelson
Ella Mendelson
TSTamy Shohat
Tamy Shohat
Background: In 1999, Israel became the first country to introduce an inactivated hepatitis A vaccine into its national childhood vaccination program. The objective of the present study was to evaluate the seroprevalence of hepatitis A virus antibodies in the Israeli population before and after the introduction of the program. Methods: A cross-sectional serosurvey using the National Serum Bank was conducted on 1883 and 2027 serum samples collected before and after introduction of the vaccine, respectively. Serologic tests for the presence of hepatitis A IgG antibodies were performed using an automated enzyme-linked fluorescent assay. Results: The age-adjusted seroprevalence rates of hepatitis A virus antibodies before implementation of hepatitis A vaccination program were 47.1% [95% confidence interval (CI): 44.7%–49.5%] among Jews and 82.8% (95% CI: 79.6%–85.9%) among Arabs, increasing 12 years after to 67.4% (95% CI: 64.7%–70.0%) and 88.2% (95% CI: 86.1%–90.2%), respectively. Conclusions: The seropositivity rate among Jews and Arabs increased significantly among the cohorts included in the program. However, among Jews, a significant increase in seropositivity was also detected among age groups not included in the vaccination program. The decrease in the incidence of hepatitis A in Israel is a consequence of high vaccine uptake, persistent seropositivity rates after vaccination and the considerable number of people vaccinated beyond the program.

13 September 2012 in Eurosurveillance
Verified
Journal Article
Open access
EKE Kopel
E Kopel
ZAZ Amitai
Z Amitai
MSM Savion
M Savion
YAY Aboudy
Y Aboudy
EME Mendelson
E Mendelson
RSR Sheffer
R Sheffer
A measles outbreak is affecting the Tel Aviv district, Israel, since April 2012. As of 10 September, 99 cases were confirmed, including 63 (64%) migrants of Eritrean and Sudanese origin. All genotyped cases had the African B3 genotype*. The mean age of migrant and non-migrant cases was 6.0±9.6 and 30.2±24.2 years, respectively (p<0.001). The majority of both migrant and non-migrant cases was unvaccinated. This is the second African measles B3 genotype outbreak within the World Health Organization European region in 2012.

1 May 2010 in Emerging Infectious Diseases
Verified
Journal Article
Open access
MMMichal Mandelboim
Michal Mandelboim
MHMusa Hindiyeh
Musa Hindiyeh
TMTal Meningher
Tal Meningher
EMElla Mendelson
Ella Mendelson

24 November 2016 in Eurosurveillance
Verified
Journal Article
Open access
MWMerav Weil
Merav Weil
LSLester Shulman
Lester Shulman
SHSophia Heiman
Sophia Heiman
TSTali Stauber
Tali Stauber
JAJacqueline Alfandari
Jacqueline Alfandari
DSDanit Sofer
Danit Sofer
Wild poliovirus type-2 has been eradicated, use of live type-2 vaccine has been terminated globally, and all type-2 polioviruses are under strict laboratory containment protocols. Re-emergence may arise from prolonged asymptomatic excretion of poliovirus by hospitalised primary immune deficient (PID) patients, as described here, through repeated exposure of close contacts to high titres of infected material. At this transition time, PID patients should be screened and hospital containment protocols updated in parallel with laboratory containment.

1 December 2021 in Journal of Infection
Verified
Journal Article
Closed access
EAEmilia Anis
Emilia Anis
EHEric J Haas
Eric J Haas
VIViki Indenbaum
Viki Indenbaum
SSSheperd Roee Singer
Sheperd Roee Singer
BWBruce Warshavsky
Bruce Warshavsky
SSSiegal Sadetzki
Siegal Sadetzki